Patents Assigned to Elucida Oncology, Inc.
  • Folate receptor targeted nanoparticle drug conjugates and uses thereof
    Patent number: 11957760
    Abstract: The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: April 16, 2024
    Assignee: Elucida Oncology, Inc.
    Inventors: Kai Ma, Aranapakam M. Venkatesan, Feng Chen, Fei Wu, Melik Ziya Türker, Thomas Courtney Gardinier, II, Geno J. Germano, Jr., Gregory Paul Adams, Francis Y. F. Lee
  • Folate receptor targeted nanoparticle drug conjugates and uses thereof
    Patent number: 11744897
    Abstract: The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
    Type: Grant
    Filed: July 18, 2022
    Date of Patent: September 5, 2023
    Assignee: Elucida Oncology, Inc.
    Inventors: Kai Ma, Aranapakam M. Venkatesan, Feng Chen, Fei Wu, Melik Ziya Türker, Thomas Courtney Gardinier, II, Geno J. Germano, Jr., Gregory Paul Adams, Francis Y. F. Lee